Journal
BIOCONJUGATE CHEMISTRY
Volume 21, Issue 4, Pages 715-722Publisher
AMER CHEMICAL SOC
DOI: 10.1021/bc900511j
Keywords
-
Categories
Funding
- National Heart Lung and Blood Institute of the NIH [HL80711, HL080729]
- Center of Cancer Nanotechnology Excellence [CA 119338]
- National Cancer Institute [CA86307]
Ask authors/readers for more resources
A novel nanoparticle-based dual-modality positron emission tomograph/magnetic resonance imaging (PET/MRI) contrast agent was developed. The probe consisted of a superparamagnetic iron oxide (SPIO) core coated with PEGylated phospholipids. The chelator 1,4,7,10-tetraazacyclo-dodecane-1,4,7,10-tetraacetic acid (DOTA) was conjugated to PEG termini to allow labeling with positron-emitting Cu-64. Radio labeling with Cu-64 at high yield and high purity was readily achieved. The (Cu-64-SPIO probes produced strong MR and PET signals and were stable in mouse serum for 24 h at 37 degrees C. Biodistribution and in vivo PET/CT imaging studies of the probes showed a circulation half-life of 143 min and high initial blood retention with moderate liver uptake, making them an attractive contrast agent for disease studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available